Last reviewed · How we verify
NCT05143710
The Clinical and Prognostic Features of PRES
trial testing PRES in PE or E in Posterior Reversible Encephalopathy Syndrome in 354 participants. Completed in 31 January 2022.
31 January 2022
Quick facts
| Lead sponsor | Dunjin Chen |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 354 |
| Start date | 1 October 2020 |
| Primary completion | 31 January 2022 |
| Estimated completion | 31 January 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- PRES in PE or E
Conditions studied
- Posterior Reversible Encephalopathy Syndrome — all drugs for Posterior Reversible Encephalopathy Syndrome →
- Pregnancy Outcomes — all drugs for Pregnancy Outcomes →
- Preeclampsia — all drugs for Preeclampsia →
- Eclampsia — all drugs for Eclampsia →
Sponsor
Dunjin Chen — full company profile →
Who can join
Adults 16 to 50, female only, with Posterior Reversible Encephalopathy Syndrome or Pregnancy Outcomes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine the features of clinical imaging, disease severity and pregnancy outcomes in posterior reversible encephalopathy syndrome with preeclampsia or eclampsia.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05143710
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Posterior Reversible Encephalopathy Syndrome
Currently open trials in the same condition.
- NCT03470467 — Posterior Reversible Encephalopathy Syndrome in the Critically Ill Patients · recruiting
Other Dunjin Chen trials
Trials by the same sponsor.
- NCT06684080 — The Effectiveness of a Care Bundle to Prevent Postpartum Hemorrhage After Cesarean Delivery · NA · not yet recruiting
- NCT05433870 — Inflammatory Biomarkers for the Diagnosis of oPRES · completed
- NCT05310513 — The Predictors of ICU Admission of oPRES · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05143710 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dunjin Chen
- Last refreshed: 2 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05143710.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing